Table 3

SIR for subsequent hemorrhagic stroke of patients with IMD
Follow-up interval (years)
<1 1-5 5-10 > = 10 All
Immune-mediated diseases O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Addison´s disease 2 2.70 0.25 9.94 2 0.64 0.06 2.34 1 0.42 0.00 2.41 1 0.55 0.00 3.17 6 0.74 0.27 1.63
Amyotrophic lateral sclerosis 1 0.47 0.00 2.68 2 1.30 0.12 4.78 1 1.82 0.00 10.42 0 4 0.89 0.23 2.30
Ankylosing spondylitis 6 8.11 2.92 17.76 15 3.43 1.92 5.68 7 1.66 0.66 3.44 14 2.28 1.24 3.84 42 2.72 1.96 3.67
Autoimmune hemolytic anemia 1 3.13 0.00 17.91 4 2.96 0.77 7.66 1 1.15 0.00 6.59 2 2.99 0.28 10.98 8 2.49 1.06 4.93
Behcet´s disease 1 33.33 0.01 191.08 0 0 0 1 1.67 0.00 9.55
Celiac disease 2 3.57 0.34 13.13 6 2.08 0.75 4.56 7 2.69 1.07 5.58 8 2.65 1.13 5.25 23 2.54 1.61 3.81
Chorea minor 0 0 0 0 0
Crohn disease 5 1.47 0.46 3.46 47 2.60 1.91 3.46 19 1.19 0.72 1.87 24 1.57 1.00 2.34 95 1.80 1.46 2.21
Diabetes mellitus type I 0 2 2.50 0.24 9.19 1 1.11 0.00 6.37 2 1.01 0.09 3.70 5 1.32 0.42 3.10
Discoid lupus erythematosus 1 11.11 0.00 63.69 1 2.33 0.00 13.33 0 0 2 1.87 0.18 6.87
Grave´s disease 8 1.53 0.65 3.02 58 1.77 1.35 2.29 48 1.61 1.18 2.13 41 1.48 1.06 2.02 155 1.62 1.38 1.90
Hashimoto´s thyroiditis 4 1.47 0.38 3.79 27 2.01 1.32 2.93 19 2.10 1.26 3.29 11 1.37 0.68 2.46 61 1.84 1.40 2.36
Immune thrombocytopenic purpura 8 8.60 3.67 17.03 12 2.81 1.45 4.92 6 2.18 0.79 4.78 2 1.23 0.12 4.54 28 2.93 1.94 4.23
Localized scleroderma 0 1 0.93 0.00 5.36 1 0.85 0.00 4.90 6 4.32 1.55 9.46 8 2.11 0.90 4.17
Lupoid hepatitis 0 0 0 0 0
Multiple sclerosis 4 1.82 0.47 4.70 15 1.36 0.76 2.25 9 1.09 0.49 2.08 6 0.94 0.34 2.06 34 1.22 0.84 1.71
Myasthenia gravis 1 1.22 0.00 6.99 8 2.09 0.89 4.14 6 2.17 0.78 4.76 0 15 1.62 0.90 2.68
Pernicious anemia 4 2.15 0.56 5.56 18 1.67 0.99 2.65 13 1.52 0.81 2.61 7 0.99 0.39 2.06 42 1.49 1.07 2.01
Polyarteritis nodosa 2 5.41 0.51 19.88 0 0.00 0.54 2.19 3 1.91 0.36 5.66 0 5 1.00 0.31 2.34
Polymyalgia rheumatica 21 2.06 1.28 3.16 78 1.42 1.12 1.77 65 1.67 1.29 2.13 40 1.49 1.06 2.03 204 1.56 1.35 1.79
Polymyositis/ dermatomyositis 1 2.63 0.00 15.08 3 1.95 0.37 5.77 1 1.18 0.00 6.74 1 2.08 0.00 11.94 6 1.85 0.66 4.04
Primary biliary cirrhosis 1 2.08 0.00 11.94 3 1.76 0.33 5.22 2 2.17 0.20 7.99 0 6 1.87 0.67 4.10
Psoriasis 9 2.88 1.31 5.50 32 1.83 1.25 2.59 23 1.51 0.95 2.26 21 1.32 0.81 2.02 85 1.64 1.31 2.03
Reiter´s disease 0 1 2.94 0.00 16.86 1 2.56 0.00 14.70 0 2 1.42 0.13 5.22
Rheumatic fever 1 7.69 0.00 44.09 0 0 1 1.72 0.00 9.88 2 1.04 0.10 3.81
Rheumatoid arthritis 65 3.27 2.52 4.17 191 2.03 1.76 2.34 109 1.92 1.57 2.31 61 1.78 1.36 2.29 426 2.08 1.89 2.29
Sarcoidosis 3 2.48 0.47 7.34 12 1.87 0.96 3.28 14 2.26 1.23 3.80 6 0.79 0.28 1.73 35 1.64 1.14 2.28
Sjögren´s syndrome 0 3 1.35 0.25 4.00 2 1.03 0.10 3.77 0 5 0.81 0.26 1.90
Systemic lupus erythematosus 9 8.65 3.92 16.50 13 2.89 1.53 4.95 4 1.17 0.31 3.03 6 1.91 0.69 4.19 32 2.65 1.81 3.74
Systemic sclerosis 2 3.17 0.30 11.67 5 2.67 0.84 6.29 3 2.73 0.51 8.07 2 3.45 0.33 12.68 12 2.87 1.48 5.03
Ulcerative colitis 7 1.45 0.57 3.00 40 1.45 1.03 1.97 28 1.21 0.80 1.74 33 1.44 0.99 2.02 108 1.37 1.13 1.66
Wegener´s granulomatosis 6 5.83 2.10 12.76 3 0.90 0.17 2.67 2 1.08 0.10 3.95 0 11 1.47 0.73 2.63
All 175 2.65 2.27 3.08 602 1.83 1.69 1.98 396 1.63 1.47 1.80 295 1.47 1.31 1.65 1468 1.75 1.66 1.84

O = observed number of cases; SIR = standardized incidence ratio; CI = confidence interval.

Bold type: 95% CI does not include 1.00.

Adjusted for age, period, socioeconomic status, region of residence, hospitalization of chronic lower respiratory diseases, obesity, alcoholism, hypertension, diabetes, atrial fibrillation, heart failure, renal disease, sepsis, and coronary heart disease.

Zöller et al.

Zöller et al. BMC Neurology 2012 12:41   doi:10.1186/1471-2377-12-41

Open Data